Lineage Cell Therapeutics (LCTX) Assets Average (2011 - 2026)

Lineage Cell Therapeutics has reported Assets Average for 16 years, with the latest figure at $111.1 million in Q1 2026.

• For the quarter ending Q1 2026, Assets Average fell 1.27% year-over-year to $111.1 million; the trailing twelve-month figure through Mar 2026 stood at $111.1 million (down 1.27% YoY), and the FY2025 full-year result was $112.9 million, up 5.4% from the prior year.
• Assets Average for Q1 2026 stood at $111.1 million, up from $101.1 million in the prior quarter.
• The five-year high for Assets Average was $159.5 million in Q1 2022, with the low at $90.2 million in Q3 2025.
• Historically, Assets Average has averaged $113.8 million across 5 years, with a median of $108.9 million in 2023.
• Annual changes were most pronounced in 2022 — Assets Average soared 35.27% — and 2023, when it fell 25.76%.
• Lineage Cell Therapeutics' Assets Average stood at $127.4 million in 2022, then fell by 18.7% to $103.6 million in 2023, then advanced by 1.27% to $104.9 million in 2024, then declined by 3.62% to $101.1 million in 2025, then climbed by 9.84% to $111.1 million in 2026.
• The last three Assets Average figures came in at $111.1 million (Q1 2026), $101.1 million (Q4 2025), and $90.2 million (Q3 2025), per Business Quant data.